The pharmaceutical industry today faces one of the most complex challenges in environmental management: the effective treatment of wastewater containing active pharmaceutical ingredients, solvents, and other micropollutants. With the entry into force of the new European Directive 2024/3019 on urban wastewater treatment, more stringent requirements for the removal of APIs (active pharmaceutical ingredients) have been introduced. Therefore, the pharmaceutical sector in particular is required to review and upgrade its water purification systems before discharge. This issue is often referred to by the acronyms PIE (Pharmaceuticals in Environment) and ERP (Extended Producer Responsibility).
API production generates particularly complex effluents, characterised by the presence of organic substances that are difficult to biodegrade and pollutants that can have significant impacts on the aquatic environment, even at very low concentrations. These contaminants, if not adequately removed, can contribute to antibiotic resistance and alter aquatic ecosystems.
European environmental regulations are rapidly evolving to address this issue. The revision of the Urban Wastewater Treatment Directive, with a particular focus on API removal, requires advanced treatment technologies and guaranteed performance. For the pharmaceutical industry, this means investing in innovative technological solutions that often integrate existing on-site biological treatments.
In this new regulatory context, it is essential to evaluate quaternary treatment systems capable of:
>Effectively removing COD (Chemical Oxygen Demand), which is organic and inorganic matter that is not readily biodegradable.
>Reducing micropollutants, including active pharmaceutical ingredients, present in effluents.
>Ensuring compliance with increasingly stringent discharge limits.
>Ensuring consistent performance by improving predictive maintenance.
A Case Study: A Solution for a European API Manufacturer
A major pharmaceutical chemical company, with six production sites in Europe, worked with us to solve these challenges at its French plant. The company needed to implement a quaternary treatment system to complement and enhance its existing purification plant, ensuring compliance with environmental regulations and the effective removal of micropollutants specific to its production.
Client Challenges
We faced a common but critical issue: controlling refractory COD, the organic and inorganic matter that is not easily degraded by conventional biological treatment methods and requires more oxygen.
Furthermore, due to the unique characteristics of pharmaceutical production, the effluents contained active ingredients that needed to be removed with specific treatments. Therefore, we needed to implement a complementary advanced treatment process and upgrade the existing plant, ensuring measurable results and regulatory compliance.
The proposed solution: complementary technologies for guaranteed results
The client relied on Veolia's expertise to develop a customised solution. The technical team conducted an assessment of the wastewater characteristics and the performance of the existing system to fully understand the technical requirements.
This study identified the need for three technologies that could be integrated: an ozone generator, a Moving Bed Biofilm Reactor (MBBR), and disc filters.
The system we offered also increased treatment capacity by an additional 250 cubic meters per hour (m³/h), with the possibility of further expansion in the future.
Benefits for the client
The design and implementation of this solution have yielded concrete and measurable benefits in terms of:
>Regulatory compliance: ensuring compliance with current and future discharge standards, with ample safety margins that protect against potential regulatory tightening.
>Environmental protection: effective removal of active pharmaceutical ingredients, contributing to the protection of aquatic ecosystems and reducing the risk of antibiotic resistance.
>Operational reliability: robust system backed by a three-year warranty, ensuring production continuity and minimising operational risks.
>Management peace of mind: guaranteed performance that eliminates environmental compliance concerns, allowing the customer to focus on their core business.
>Scalability: possibility of future plant expansion to accommodate production growth without the need for a complete redesign
Why Invest in Advanced Pharmaceutical Wastewater Treatment
The case study presented highlights some key elements that every pharmaceutical manufacturer should consider when expanding their plant:
>Anticipate Regulations: Investing in advanced technologies today means preparing plants ahead of time to meet tomorrow's regulations, avoiding costly upgrades.
>Integrated Approach: No single technology can solve all pharmaceutical wastewater issues. It is therefore necessary to integrate several complementary solutions.
>Guaranteed Performance: It is more cost-effective to rely on partners who can guarantee specific and measurable results, capable of providing more than just individual equipment.
>Industry Experience: In-depth knowledge of the pharmaceutical industrial process makes the difference in designing effective solutions that focus on the customer's specific challenges.
>Long-Term Support: Extended warranties and ongoing technical support ensure the plant's performance is maintained over time.
Conclusion:
The pharmaceutical sector plays a crucial role in public health and also has a responsibility to minimise its environmental impact, given its significant industrial presence in our country. Advanced wastewater treatment is no longer an option, but a necessity to ensure the long-term sustainability of production activities.
This case study demonstrates how Veolia's integrated approach combines technical and process expertise, innovative technologies, and performance guarantees. It can also transform wastewater treatment challenges into opportunities to improve environmental performance, ensure regulatory compliance, and ensure business continuity.
With the current regulatory environment, characterised by revisions, updates, and growing expectations for environmental sustainability, investing in advanced treatment solutions is not only a regulatory requirement, but also a competitive advantage and a key element in sustainability reporting and corporate social responsibility.
